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Background
TRPC3 was recently demonstrated as a player in pathogen-
esis of cardiac hypertrophy, while the potential pro-
arrhythmogenic role of TRPC3 is incompletely understood.
Using a TRPC3 transgenic overexpression mouse model,
we examined the involvement of TRPC3 in cardiac actions
of angiotensin II (AngII).
Methods
AngII effects on cardiac functions were characterized in
Langendorff perfused hearts. Single ventricular myocytes
were isolated and field-stimulated to measure effects on
sarcomere shortening and Ca2+ transients. Furthermore,
L-type Ca2+ channel current, action potentials and non-
selective ion currents were analyzed electrophysiologically.
Results
AngII (100 nM) reduced left ventricular pressure (LVP)
within 2 min to 64%, +dP/dt to 50% and −dP/dt to 55% of
control in TRPC3(+/−) hearts, while even producing a
positive inotropic effect in wild-type (WT) hearts. Simulta-
neously, ECG recordings demonstrated AngII-induced
episodes of acute arrhythmogenicity in all TRPC3(+/−)
hearts (n = 6), whereas rhythm of WT hearts (n = 6)
remained unaffected. The AngII-induced impairment of
cardiac functions in TRPC3(+/−) hearts was partially
reversed by Pyr3 (30 µM). The amplitude of Ca2+ transient
was significantly higher (p < 0.05; n = 60) in myocytes
from TRPC3(+/−) mice ([Ca2+] F/F0 0.354 ± 0.024) as
compared to WT ([Ca2+] F/F0 0.262 ± 0.021). Also, the
time constant (τ) of Ca2+ decline was different between
WT (0.196 ± 0.009 ms; n = 61) and TRPC3(+/−) (0.170 ±
0.008; n = 67; p < 0.05). Sarcomere shortening showed no
significant difference between the two groups (3.80 ±
0.69% vs. 3.52 ± 0.65%; n = 10) whereas the SR-loading
estimated from rapid application of caffeine (20 mM)
revealed an increased SR loading of up to 40% in TRPC3
(+/−) myocytes as compared to WT (p < 0.05; n = 43).
The time constant of Ca2+ decline during caffeine chal-
lenge was also significantly changed (p < 0.05) in TRPC3
(+/−) myocytes (3.04 ± 0.44 ms; n = 11) as compared to
WT cells (1.65 ± 0.158 ms; n = 16). Importantly, AngII
(100 nM) induced a rise in diastolic Ca2+ levels, which was
accompanied by irregular contractions in TRPC3(+/−) but
not in WT myocytes. The rise in the diastolic Ca2+ levels
was significantly suppressed by Pyr3 (10 µM; n = 16), SEA
0400 (1 µM; n = 14) and KN-93 (1 µM; n = 12). Electro-
physiological characterization of L-type voltage-gated Ca2+
currents and action potentials revealed that baseline elec-
trophysiological parameters were not affected by TRPC3
overexpression, while AngII induced a transient prolonga-
tion of action potential duration only in TRPC3(+/−) myo-
cytes. This TRPC3-dependent response was associated
with a higher incidence of delayed afterdepolarizations.
Conclusions
Our results demonstrate that AngII modulation of car-
diac functions is strictly dependent on TRPC3 expres-
sion and suggest a key role of TRPC channels in AngII-
mediated arrhythmogenicity.
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